Report cover image

Liquid Biopsy Market

Publisher Grand View Research
Published Jan 06, 2026
Length 150 Pages
SKU # GV20873100

Description

Liquid Biopsy Market Summary

The global liquid biopsy market size was estimated at USD 13.60 billion in 2025 and is projected to reach USD 32.57 billion by 2033, growing at a CAGR of 11.52% from 2026 to 2033. The industry is witnessing growth due to factors such as the growing prevalence of cancer, technological advancements in cancer diagnostics, and rising preference for minimally invasive cancer diagnostics.

Moreover, ongoing research for the development of liquid biopsy assays and tests, aided by the rising adoption and development of multi-cancer early detection tests, is providing a major opportunity for the growth of the overall market. Liquid biopsy is an advanced testing technology for the detection of genetic alterations related tumor. It has also been utilized to stratify tumors and deliver precise cancer treatment. For instance, in January 2023, Guardant Health received FDA approval for Guardant360 CDx, its liquid biopsy assay as companion diagnostics for ESR1 mutant breast cancer diagnosis. These recent innovations, advancements, and expansions in the industry promoting the use of liquid biopsy are driving the market.

Global Liquid Biopsy Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global liquid biopsy market report based on sample type, biomarker, technology, application, end use, clinical application, product, and region:
  • Sample Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Blood Sample
  • Others
  • Biomarker Outlook (Revenue, USD Billion, 2021 - 2033)
  • Circulating Tumor Cells (CTCs)
  • Circulating Nucleic Acids
  • Exosomes/Microvesicles
  • Others
  • Technology Outlook (Revenue, USD Billion, 2021 - 2033)
  • Multi-gene parallel Analysis (NGS)
  • Single Gene Analysis (PCR Microarrays)
  • Application Outlook (Revenue, USD Billion, 2021 - 2033)
  • Cancer
  • Lung Cancer
  • Prostate Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Gastrointestinal Cancer
  • Others
  • Reproductive Health
  • Others
  • End Use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals and Laboratories
  • Specialty Clinics
  • Academic and Research Centers
  • Others
  • Clinical Application Outlook (Revenue, USD Billion, 2021 - 2033)
  • Therapy Selection
  • Treatment Monitoring
  • Early Cancer Screening
  • Recurrence Monitoring
  • Others
  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Instruments
  • Consumables Kits and Reagents
  • Software and Services
  • Regional Outlook (Revenue, USD Billion, 2021- 2033)
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

150 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. OBJECTIVE - 1
1.2.2. OBJECTIVE - 2
1.2.3. OBJECTIVE - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. PURCHASED DATABASE
1.4.2. GVR’S INTERNAL DATABASE
1.4.3. SECONDARY SOURCES
1.4.4. PRIMARY RESEARCH
1.5. Information or Data Analysis
1.5.1. DATA ANALYSIS MODELS
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. COMMODITY FLOW ANALYSIS
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.4.1. Increasing prevalence of cancer
3.4.2. Growing geriatric population
3.4.3. Technological advancements
3.4.4. Increasing preference for noninvasive treatment
3.5. Market Restraint Analysis
3.5.1. Patent expiry of blockbuster drugs prescribed
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
Chapter 4. Sample Type Business Analysis
4.1. Liquid Biopsy Market: Type Movement Analysis
4.2. Blood Sample
4.2.1. Blood Sample Market, 2021 - 2033 (USD Million)
4.3. Others
4.3.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. Biomarker Business Analysis
5.1. Liquid Biopsy Market: Biomarker Movement Analysis
5.2. Circulating Tumor Cells (CTCs)
5.2.1. Circulating Tumor Cells (CTCs) Market, 2021 - 2033 (USD Million)
5.3. Circulating Nucleic Acids
5.3.1. Circulating Nucleic Acids Market, 2021 - 2033 (USD Million)
5.4. Exosomes/Microvesicles
5.4.1. Exosomes/Microvesicles Market, 2021 - 2033 (USD Million)
5.5. Others
5.5.1. Others Market, 2021 - 2033 (USD Million)
Chapter 6. Technology Business Analysis
6.1. Liquid Biopsy Market: Technology Movement Analysis
6.2. Multi-gene-parallel Analysis (NGS)
6.2.1. Multi-gene-parallel Analysis (NGS) Market, 2021 - 2033 (USD Million)
6.3. Single Gene Analysis (PCR Microarrays)
6.3.1. Single Gene Analysis (PCR Microarrays) Market, 2021 - 2033 (USD Million)
Chapter 7. Application Business Analysis
7.1. Liquid Biopsy Market: Application Movement Analysis
7.2. Cancer
7.2.1. Cancer Market, 2021 - 2033 (USD Million)
7.2.1.1. Lung Cancer
7.2.1.1.1. Lung Cancer Market, 2021 - 2033 (USD Million)
7.2.1.2. Prostate Cancer
7.2.1.2.1. Prostate Cancer Market, 2021 - 2033 (USD Million)
7.2.1.3. Breast Cancer
7.2.1.3.1. Breast Cancer Market, 2021 - 2033 (USD Million)
7.2.1.4. Colorectal Cancer
7.2.1.4.1. Colorectal Cancer Market, 2021 - 2033 (USD Million)
7.2.1.5. Leukemia
7.2.1.5.1. Leukemia Market, 2021 - 2033 (USD Million)
7.2.1.6. Gastrointestinal Cancer
7.2.1.6.1. Gastrointestinal Cancer Market, 2021 - 2033 (USD Million)
7.2.1.7. Others
7.2.1.7.1. Others Market, 2021 - 2033 (USD Million)
7.3. Reproductive Health
7.3.1. Reproductive Health Market, 2021 - 2033 (USD Million)
7.4. Others
7.4.1. Others Market, 2021 - 2033 (USD Million)
Chapter 8. End Use Business Analysis
8.1. Liquid Biopsy Market: End-Use Movement Analysis
8.2. Hospitals and Laboratories
8.2.1. Hospitals and Laboratories Market, 2021 - 2033 (USD Million)
8.3. Specialty Clinics
8.3.1. Specialty Clinics Market, 2021 - 2033 (USD Million)
8.4. Academic and Research Centers
8.4.1. Academic and Research Centers Market, 2021 - 2033 (USD Million)
8.5. Others
8.5.1. Others Liquid Biopsy Market, 2021 - 2033 (USD Million)
Chapter 9. Clinical Application Business Analysis
9.1. Liquid Biopsy Market: Clinical Application Movement Analysis
9.2. Therapy Selection
9.2.1. Therapy Selection Market, 2021 - 2033 (USD Million)
9.3. Treatment Monitoring
9.3.1. Treatment Monitoring Market, 2021 - 2033 (USD Million)
9.4. Early Cancer Screening
9.4.1. Early Cancer Screening Market, 2021 - 2033 (USD Million)
9.5. Recurrence Monitoring
9.5.1. Recurrence Monitoring Market, 2021 - 2033 (USD Million)
9.6. Others
9.6.1. Others Liquid Biopsy Market, 2021 - 2033 (USD Million)
Chapter 10. Product Business Analysis
10.1. Liquid Biopsy Market: Product Movement Analysis
10.2. Instruments
10.2.1. Instruments Market, 2021 - 2033 (USD Million)
10.3. Consumables Kits and Reagents
10.3.1. Consumables Kits and Reagents Market, 2021 - 2033 (USD Million)
10.4. Software and Services
10.4.1. Software and Services Market, 2021 - 2033 (USD Million)
Chapter 11. Regional Business Analysis
11.1. Liquid Biopsy Market Share By Region, 2025 & 2033
11.2. North America
11.2.1. North America Liquid biopsy market, 2021 - 2033 (USD Million)
11.2.2. U.S.
11.2.2.1. Key Country Dynamics
11.2.2.2. Target Disease Prevalence
11.2.2.3. Competitive Scenario
11.2.2.4. Regulatory Framework
11.2.2.5. Reimbursement Scenario
11.2.2.6. U.S. Liquid biopsy market, 2021 - 2033 (USD MILLION)
11.2.3. Canada
11.2.3.1. Key Country Dynamics
11.2.3.2. Target Disease Prevalence
11.2.3.3. Competitive Scenario
11.2.3.4. Regulatory Framework
11.2.3.5. Reimbursement Scenario
11.2.3.6. Canada Liquid biopsy market, 2021 - 2033 (USD Million)
11.2.4. Mexico
11.2.4.1. Key Country Dynamics
11.2.4.2. Target Disease Prevalence
11.2.4.3. Competitive Scenario
11.2.4.4. Regulatory Framework
11.2.4.5. Reimbursement Scenario
11.2.4.6. Mexico Liquid biopsy market, 2021 - 2033 (USD Million)
11.3. Europe
11.3.1. Europe Liquid biopsy market, 2021 - 2033 (USD Million)
11.3.2. Germany
11.3.2.1. Key Country Dynamics
11.3.2.2. Target Disease Prevalence
11.3.2.3. Competitive Scenario
11.3.2.4. Regulatory Framework
11.3.2.5. Reimbursement Scenario
11.3.2.6. Germany Liquid biopsy market, 2021 - 2033 (USD Million)
11.3.3. UK
11.3.3.1. Key Country Dynamics
11.3.3.2. Target Disease Prevalence
11.3.3.3. Competitive Scenario
11.3.3.4. Regulatory Framework
11.3.3.5. Reimbursement Scenario
11.3.3.6. UK Liquid biopsy market, 2021 - 2033 (USD Million)
11.3.4. France
11.3.4.1. Key Country Dynamics
11.3.4.2. Target Disease Prevalence
11.3.4.3. Competitive Scenario
11.3.4.4. Regulatory Framework
11.3.4.5. Reimbursement Scenario
11.3.4.6. France Liquid biopsy market, 2021 - 2033 (USD Million)
11.3.5. Italy
11.3.5.1. Key Country Dynamics
11.3.5.2. Target Disease Prevalence
11.3.5.3. Competitive Scenario
11.3.5.4. Regulatory Framework
11.3.5.5. Reimbursement Scenario
11.3.5.6. Italy Liquid biopsy market, 2021 - 2033 (USD Million)
11.3.6. Spain
11.3.6.1. Key Country Dynamics
11.3.6.2. Target Disease Prevalence
11.3.6.3. Competitive Scenario
11.3.6.4. Regulatory Framework
11.3.6.5. Reimbursement Scenario
11.3.6.6. Spain Liquid biopsy market, 2021 - 2033 (USD Million)
11.3.7. Denmark
11.3.7.1. Key Country Dynamics
11.3.7.2. Target Disease Prevalence
11.3.7.3. Competitive Scenario
11.3.7.4. Regulatory Framework
11.3.7.5. Reimbursement Scenario
11.3.7.6. Denmark Liquid biopsy market, 2021 - 2033 (USD Million)
11.3.8. Sweden
11.3.8.1. Key Country Dynamics
11.3.8.2. Target Disease Prevalence
11.3.8.3. Competitive Scenario
11.3.8.4. Regulatory Framework
11.3.8.5. Reimbursement Scenario
11.3.8.6. Sweden Liquid biopsy market, 2021 - 2033 (USD Million)
11.3.9. Norway
11.3.9.1. Key Country Dynamics
11.3.9.2. Target Disease Prevalence
11.3.9.3. Competitive Scenario
11.3.9.4. Regulatory Framework
11.3.9.5. Reimbursement Scenario
11.3.9.6. Norway Liquid biopsy market, 2021 - 2033 (USD Million)
11.4. Asia Pacific
11.4.1. Asia Pacific Liquid biopsy market, 2021 - 2033 (USD Million)
11.4.2. Japan
11.4.2.1. Key Country Dynamics
11.4.2.2. Target Disease Prevalence
11.4.2.3. Competitive Scenario
11.4.2.4. Regulatory Framework
11.4.2.5. Reimbursement Scenario
11.4.2.6. Japan Liquid biopsy market, 2021 - 2033 (USD Million)
11.4.3. China
11.4.3.1. Key Country Dynamics
11.4.3.2. Target Disease Prevalence
11.4.3.3. Competitive Scenario
11.4.3.4. Regulatory Framework
11.4.3.5. Reimbursement Scenario
11.4.3.6. China Liquid biopsy market, 2021 - 2033 (USD Million)
11.4.4. India
11.4.4.1. Key Country Dynamics
11.4.4.2. Target Disease Prevalence
11.4.4.3. Competitive Scenario
11.4.4.4. Regulatory Framework
11.4.4.5. Reimbursement Scenario
11.4.4.6. India Liquid biopsy market, 2021 - 2033 (USD Million)
11.4.5. South Korea
11.4.5.1. Key Country Dynamics
11.4.5.2. Target Disease Prevalence
11.4.5.3. Competitive Scenario
11.4.5.4. Regulatory Framework
11.4.5.5. Reimbursement Scenario
11.4.5.6. South Korea Liquid biopsy market, 2021 - 2033 (USD Million)
11.4.6. Australia
11.4.6.1. Key Country Dynamics
11.4.6.2. Target Disease Prevalence
11.4.6.3. Competitive Scenario
11.4.6.4. Regulatory Framework
11.4.6.5. Reimbursement Scenario
11.4.6.6. Australia Liquid biopsy market, 2021 - 2033 (USD Million)
11.4.7. Thailand
11.4.7.1. Key Country Dynamics
11.4.7.2. Target Disease Prevalence
11.4.7.3. Competitive Scenario
11.4.7.4. Regulatory Framework
11.4.7.5. Reimbursement Scenario
11.4.7.6. Thailand Liquid biopsy market, 2021 - 2033 (USD Million)
11.5. Latin America
11.5.1. Latin America Liquid biopsy market, 2021 - 2033 (USD Million)
11.5.2. Brazil
11.5.2.1. Key Country Dynamics
11.5.2.2. Target Disease Prevalence
11.5.2.3. Competitive Scenario
11.5.2.4. Regulatory Framework
11.5.2.5. Reimbursement Scenario
11.5.2.6. Brazil Liquid biopsy market, 2021 - 2033 (USD Million)
11.5.3. Argentina
11.5.3.1. Key Country Dynamics
11.5.3.2. Target Disease Prevalence
11.5.3.3. Competitive Scenario
11.5.3.4. Regulatory Framework
11.5.3.5. Reimbursement Scenario
11.5.3.6. Argentina Liquid biopsy market, 2021 - 2033 (USD Million)
11.6. Middle East and Africa
11.6.1. Middle East and Africa Liquid biopsy market, 2021 - 2033 (USD Million)
11.6.2. South Africa
11.6.2.1. Key Country Dynamics
11.6.2.2. Target Disease Prevalence
11.6.2.3. Competitive Scenario
11.6.2.4. Regulatory Framework
11.6.2.5. Reimbursement Scenario
11.6.2.6. South Africa Liquid biopsy market, 2021 - 2033 (USD Million)
11.6.3. Saudi Arabia
11.6.3.1. Key Country Dynamics
11.6.3.2. Target Disease Prevalence
11.6.3.3. Competitive Scenario
11.6.3.4. Regulatory Framework
11.6.3.5. Reimbursement Scenario
11.6.3.6. Saudi Arabia Liquid biopsy market, 2021 - 2033 (USD Million)
11.6.4. UAE
11.6.4.1. Key Country Dynamics
11.6.4.2. Target Disease Prevalence
11.6.4.3. Competitive Scenario
11.6.4.4. Regulatory Framework
11.6.4.5. Reimbursement Scenario
11.6.4.6. UAE Liquid biopsy market, 2021 - 2033 (USD Million)
11.6.5. Kuwait
11.6.5.1. Key Country Dynamics
11.6.5.2. Target Disease Prevalence
11.6.5.3. Competitive Scenario
11.6.5.4. Regulatory Framework
11.6.5.5. Reimbursement Scenario
11.6.5.6. Kuwait Liquid biopsy market, 2021 - 2033 (USD Million)
Chapter 12. Competitive Landscape
12.1. Participant’s overview
12.2. Financial performance
12.3. Participant categorization
12.3.1. Market Leaders
12.3.2. Liquid Biopsy Market Share Analysis, 2025
12.3.3. Company Profiles
12.3.3.1. ANGLE plc
12.3.3.1.1. Company Overview
12.3.3.1.2. Financial Performance
12.3.3.1.3. Product Benchmarking
12.3.3.1.4. Strategic Initiatives
12.3.3.2. Oncimmune Holdings PLC
12.3.3.2.1. Company Overview
12.3.3.2.2. Financial Performance
12.3.3.2.3. Product Benchmarking
12.3.3.2.4. Strategic Initiatives
12.3.3.3. Guardant Health
12.3.3.3.1. Company Overview
12.3.3.3.2. Financial Performance
12.3.3.3.3. Product Benchmarking
12.3.3.3.4. Strategic Initiatives
12.3.3.4. Myriad Genetics, Inc.
12.3.3.4.1. Company Overview
12.3.3.4.2. Financial Performance
12.3.3.4.3. Product Benchmarking
12.3.3.4.4. Strategic Initiatives
12.3.3.5. Biocept, Inc.
12.3.3.5.1. Company Overview
12.3.3.5.2. Financial Performance
12.3.3.5.3. Product Benchmarking
12.3.3.5.4. Strategic Initiatives
12.3.3.6. Lucence Health Inc.
12.3.3.6.1. Company Overview
12.3.3.6.2. Financial Performance
12.3.3.6.3. Product Benchmarking
12.3.3.6.4. Strategic Initiatives
12.3.3.7. Freenome Holdings, Inc.
12.3.3.7.1. Company Overview
12.3.3.7.2. Financial Performance
12.3.3.7.3. Product Benchmarking
12.3.3.7.4. Strategic Initiatives
12.3.3.8. F. Hoffmann-La Roche Ltd.
12.3.3.8.1. Company Overview
12.3.3.8.2. Financial Performance
12.3.3.8.3. Product Benchmarking
12.3.3.8.4. Strategic Initiatives
12.3.3.9. QIAGEN
12.3.3.9.1. Company Overview
12.3.3.9.2. Financial Performance
12.3.3.9.3. Product Benchmarking
12.3.3.9.4. Strategic Initiatives
12.3.3.10. Illumina, Inc.
12.3.3.10.1. Company Overview
12.3.3.10.2. Financial Performance
12.3.3.10.3. Product Benchmarking
12.3.3.10.4. Strategic Initiatives
12.3.3.11. Thermo Fisher Scientific, Inc.
12.3.3.11.1. Company Overview
12.3.3.11.2. Financial Performance
12.3.3.11.3. Product Benchmarking
12.3.3.11.4. Strategic Initiatives
12.3.3.12. Epigenomics AG
12.3.3.12.1. Company Overview
12.3.3.12.2. Financial Performance
12.3.3.12.3. Product Benchmarking
12.3.3.12.4. Strategic Initiatives
12.3.4. Strategy Mapping
12.3.4.1. Expansion
12.3.4.2. Acquisition
12.3.4.3. Collaborations
12.3.4.4. Disease Type/Drug Class Launch
12.3.4.5. Partnerships
12.3.4.6. Others

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us